RxDoctor Payments Data

Brian Kolski, MD

Interventional Cardiology · Orange, CANPI 1851449896

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 20.2%. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$533,676in general payments, 2019–2025

Across 1,475 payments — averaging $361.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$108K
  • Shockwave Medical, Inc$84K
  • Abbott$80K
  • Penumbra, Inc.$75K
  • Cardiovascular Systems Inc.$53K
  • Cordis US CORP.$41K
  • plus $93K from 51 others
$35,255in research payments, 2019–2025

Across 19 payments — averaging $1855.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$16K
  • Abbott$10K
  • Biotronik Inc.$10K
  • Abiomed$30

What the payments were for

  • Consulting fees$113,87821%
  • Speaking & faculty fees$298,02356%
  • Travel & lodging$66,94413%
  • Food & beverage$54,19710%
  • Education$2780%
  • Gifts$750%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$533,676 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$580,562
Medicare patients
652
Services billed
3,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$675,339
EliquisApixaban231$268,448
EntrestoSacubitril/Valsartan142$178,086
XareltoRivaroxaban32$37,872
Repatha SureclickEvolocumab39$27,944
Praluent PenAlirocumab21$23,526
FarxigaDapagliflozin Propanediol18$16,172
MounjaroTirzepatide12$11,936
BrilintaTicagrelor15$11,576
Repatha PushtronexEvolocumab15$10,781
InpefaSotagliflozin14$7,965
Repatha SyringeEvolocumab11$6,020
Metoprolol Succinate211$3,383
Atorvastatin Calcium283$3,226
Rosuvastatin Calcium157$2,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$514$943,787256 claims
NovartisEntresto$1,230$178,086142 claims
Johnson & JohnsonXarelto$304$37,87232 claims
AstraZenecaFarxiga, Brilinta$140$27,74833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →